Eugia warning letter resolution uncertainty
Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.
high · analyst_question
Aurobindo Pharma Limited — Q3 FY26
Aurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
6-APA predatory pricing impact
6-APA prices have been below cost of manufacture internationally, causing losses; correction expected by April but timing uncertain.
medium · management_commentaryLannett acquisition regulatory delays
FTC approval process is ongoing; any delay or unexpected conditions could impact the timeline and synergies.
medium · analyst_questionRamp-up costs from multiple greenfield projects
EBITDA burn from ramping up facilities like Pen G, Dayton, Raleigh, and biosimilars may pressure near-term margins.
medium · data_observation